Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deprescribing PPIs to Reduce HE Risk After TIPS
NCT05070351Phase 2Completed
- Sponsor
- Duke University
- Start
- Jan 2022
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatic encephalopathy (HE) (2 arms), sponsored by Duke University. Primary endpoint: Change in Minimal Hepatic Encephalopathy. Started Jan 2022; status: completed.
02
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT05070351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070351.